Abstract
Tuberous sclerosis complex (TSC), a rare genetic disorder affects over 50,000 people in the United States (US). The disease burden of facial angiofibroma (FA), the most predominant cutaneous manifestation of TSC, is substantial. We aimed to document healthcare resource utilization (HCRU) and costs related with management of TSC and in a subset of TSC patients with FA.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
